Company intelligence / Profile preview
RenRen Applied Cell Biotechnology
- Ownership
- Private
- Development stage
- Other
Overview
RenRen Applied Cell Biotechnology is a Chinese biopharmaceutical company focused on the development of next-generation cell therapies for the treatment of solid tumors and hematological malignancies. The company leverages its proprietary platforms to engineer Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies designed to overcome the immunosuppressive microenvironment of solid tumors. RenRen Applied Cell is particularly active in the development of universal, off-the-shelf cell products (UCAR-T) to improve accessibility and reduce manufacturing costs. Their research pipeline targets high-unmet-need indications such as pancreatic, ovarian, and liver cancers.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyT cell receptor engineered T cell therapy
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on RenRen Applied Cell Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RenRen Applied Cell Biotechnology.